Early Phase Support for Plasmid DNA Supply to Secure Future Manufacturing
Summary: One significant challenge in the manufacturing of cell and gene therapies is the production of high quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines.
The market for cell and gene therapies has grown rapidly over the last few years and will likely continue as more therapies reach pivotal trials. This rapid emergence of cell and gene therapies has fuelled demand for plasmids and has created a manufacturing ‘bottleneck’.